Tìm theo
Ipratropium bromide
Các tên gọi khác (10 ) :
  • (Endo,syn)-(+-)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
  • 3alpha-Hydroxy-8-isopropyl-1alphah,5alphah-tropanium bromide (+-)-tropate
  • 8-Isopropylnoratropine methobromide
  • Bromure d'ipratropium
  • Bromuro de ipratropio
  • Ipratropii bromidum
  • Ipratropium bromide (anhydrous)
  • Ipratropium bromide anhydrous
  • Ipratropiumbromid
  • N-Isopropylnoratropinium bromomethylate
bronchodilator agents, muscarinic antagonists, cholinergic antagonists, antispasmodics
Thuốc Gốc
Small Molecule
CAS: 60205-81-4
ATC: R01AX03, R03BB01
ĐG : 3M Health Care , http://www.3m.com
CTHH: C20H30BrNO3
PTK: 412.361
A muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C20H30BrNO3
Phân tử khối
412.361
Monoisotopic mass
411.140906478
InChI
InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18+,19?,21+;
InChI Key
InChIKey=LHLMOSXCXGLMMN-VVQPYUEFSA-M
IUPAC Name
(1R,3R,5S,8R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide
Traditional IUPAC Name
ipratropium bromide
SMILES
[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C
Độ tan chảy
230-231.5
Độ hòa tan
Freely soluble
logP
-1.8
logS
-5.8
pKa (strongest acidic)
15.15
pKa (Strongest Basic)
-2.7
PSA
46.53 Å2
Refractivity
105.9 m3·mol-1
Polarizability
37.43 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
2
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
3
Bioavailability
1
Rule of Five
true
MDDR-Like Rule
true
Dược Lực Học : Ipratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.
Cơ Chế Tác Dụng : A muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. [PubChem] Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.
Dược Động Học :
▧ Absorption :
Inhalation (local)-minimal; Nasal-rapid and minimal
▧ Volume of Distribution :
* 4.6 L/kg
▧ Protein binding :
Minimally (0 to 9% in vitro) bound to plasma albumin and α1-acid glycoproteins
▧ Metabolism :
Partially metabolized to at least 8 metabolites formed primarily via hydrolysis and conjugation. The main metabolites are N-isopropylnortropium methobromide, which is formed by enzymatic hydrolysis of the ester; α-phenylacrylic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a water; and phenylacetic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a CH3OH-group. These metabolites appear to be inactive.
▧ Route of Elimination :
Primarily eliminated renally via active secretion.
▧ Half Life :
2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t1/2 α) and terminal elimination-phase half-life (t1/2 β) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.
▧ Clearance :
* 2.3 L/min (total clearance of active ingredient)
Độc Tính : LD50=1001mg/kg (orally in mice)
Chỉ Định : For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Tương Tác Thuốc :
  • Tacrine The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ipratropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
  • Trimethobenzamide Trimethobenzamide and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Triprolidine Triprolidine and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
  • Trospium Trospium and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Liều Lượng & Cách Dùng : Aerosol, metered - Nasal - 21 mcg, 42 mcg
Solution - Respiratory (inhalation) - 0.0125%, 0.02%, 0.025%
Spray, metered - Nasal - 17 mcg, 20 mcg
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Teva
    Sản phẩm biệt dược : Aerovent
  • Công ty : Apotex Inc.
    Sản phẩm biệt dược : Apovent
  • Sản phẩm biệt dược : Atronase
  • Sản phẩm biệt dược : Atrovent
  • Công ty :
    Sản phẩm biệt dược : AtroventHFA
  • Công ty : Ivax
    Sản phẩm biệt dược : Ipraxa
  • Công ty : Cipla Medpro
    Sản phẩm biệt dược : Ipvent
  • Sản phẩm biệt dược : Rhinovent
  • Sản phẩm biệt dược : Rinatec
  • Công ty : Valeas
    Sản phẩm biệt dược : Rinovagos
Đóng gói
... loading
... loading